The CoreValve System is designed to provide a minimally invasive, transcatheter treatment option for patients with symptomatic, severe aortic stenosis who are at high risk or are ineligible for open-heart surgery. Worldwide, approximately 300,000 people have been diagnosed with this condition (100,000 in the U.S.).
Approximately one-third of these patients are deemed at too high of a risk for open-heart surgery, the only therapy with significant clinical effect that is currently available in the U.S.
To read more of this story, see Tuesday's print or e-edition of the Grand Haven Tribune.
For more information about the Medtronic CoreValve U.S. Clinical Trial, visit www.aorticstenosistrial.com.
The Heart & Vascular Institute is currently enrolling patients in the trial. For more information about participating in this clinical trial, contact Dr. Merhi at 616-456-9553 or Dr. Heiser 616-459-7258, or e-mail CoreValve@spectrumhealth.org.